Experimental peptide · Reviewed August 16, 2026

CJC-1295: Human Evidence, FDA Status, and Safety

CJC-1295 can raise growth hormone and IGF-1 in humans. That measurable pharmacology is real, but it is much narrower than the recovery, sleep, physique, anti-aging, and longevity claims commonly attached to the peptide.

Human hormone-response studies exist; broad patient-important benefits and long-term safety remain unestablished.

Unapproved-drug notice

CJC-1295 is not an FDA-approved drug product. Online sale, “research use only” labeling, clinic availability, or a past compounding nomination does not establish FDA approval, clinical effectiveness, product quality, or suitability for human use [1–3].

Affiliate disclosure

Some pages may include affiliate links. If you buy through those links, The Hippie Scientist may earn a commission at no additional cost to you. Affiliate relationships do not change evidence ratings, safety warnings, product-quality criteria, or editorial conclusions.

Read our affiliate and editorial policy

What Is CJC-1295?

CJC-1295 is a synthetic growth-hormone-releasing-hormone analogue. The name is used loosely in peptide marketing, so evidence from one defined molecule or formulation should not be assumed to validate every product sold as “CJC-1295.”

The best-known human studies evaluated long-acting CJC-1295 with a drug-affinity-complex modification. Shorter-acting products marketed as “no DAC” or “Mod GRF 1-29” should not be treated as pharmacologically or clinically interchangeable with that material without direct evidence [4,5].

What the Evidence Can Show

Two controlled human pharmacology reports show that CJC-1295 can produce sustained GH and IGF-1 changes in healthy adults [4,5]. Those studies answer a pharmacology question; they do not establish a treatment effect for recovery, sleep, fat loss, muscle gain, anti-aging, or longevity.

CJC-1295 evidence by question and current conclusion
Question	Best current evidence	What it supports	What it does not establish
Can CJC-1295 raise GH and IGF-1?	Randomized placebo-controlled pharmacology studies in healthy adults [4,5]	Sustained GH/IGF-1 elevation and preserved GH pulsatility	Patient-important clinical benefit
Does it improve recovery, sleep, or body composition?	No robust controlled outcome program identified in this review	No reliable conclusion	Routine therapeutic effectiveness
Are CJC-1295 + ipamorelin stacks validated?	Marketing use substantially outruns controlled human outcome evidence	A research gap	A validated combination protocol
Is long-term safety characterized?	Limited clinical exposure plus FDA safety concerns [1,4,5]	Short-term pharmacology context	Long-duration safety or uncommon-risk estimates

FDA & Compounding Status — Checked August 16, 2026

FDA's December 4, 2024 Pharmacy Compounding Advisory Committee meeting evaluated several CJC-1295-related bulk drug substances for growth hormone deficiency [2]. FDA's current significant-safety-risk page now places CJC-1295 in the section for substances whose nominations were withdrawn and continues to describe limited clinical data and potential safety concerns [1].

FDA's current 503A framework states that bulk substances generally must satisfy the applicable monograph, approved-drug-component, or 503A-bulks-list pathway. A withdrawn nomination, a past advisory-committee discussion, clinic availability, or an RUO label is not equivalent to FDA approval [3,6].

Current CJC-1295 regulatory and compounding status
Statement	Current status
“CJC-1295 is FDA-approved.”	False
“FDA reviewed CJC-1295-related substances for possible 503A listing.”	Yes; PCAC discussed them in December 2024 [2]
“The nomination remains an active Category 1 pathway.”	No; FDA's current safety page lists CJC-1295 under withdrawn nominations [1]
“Clinic or RUO availability proves legal or clinical authorization.”	No

Safety Uncertainty

FDA identifies potential immunogenicity and peptide/API-characterization concerns for compounded CJC-1295 [1].
FDA reports serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, while noting that available clinical data are limited [1].
The human pharmacology trials were not designed to establish multi-year safety, rare adverse-event rates, or safety in medically complex populations [4,5].
Injectable products introduce additional identity, sterility, contamination, and strength risks when product quality is uncertain.

Bottom Line

CJC-1295 has real human GH/IGF-1 pharmacology. That does not make it a proven recovery, sleep, physique, anti-aging, or longevity therapy. FDA's current record remains cautious, the compounding nomination is withdrawn, and long-term human benefit and safety are not established.

Back to guides →View CJC-1295 compound profile →Read the Ipamorelin guide →

Source ledger

References

6 sources

01
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current CJC-1295 entry. Source →
02
FDA. December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee. CJC-1295-related bulk drug substances reviewed for growth hormone deficiency. Source →
03
FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Current framework and rulemaking process. Source →
04
Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PMID 16352683. PubMed →
05
Teichman SL, et al. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. PMID 17018654. PubMed →
06
FDA. Human Drug Compounding Policies and Rules. Current policy and rulemaking index. Source →